Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Working Capital Changes (2022 - 2025)

Historic Other Working Capital Changes for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to -$480000.0.

  • Day One Biopharmaceuticals' Other Working Capital Changes fell 13321.8% to -$480000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 7382.83%. This contributed to the annual value of $4.8 million for FY2024, which is 4409.99% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Other Working Capital Changes is -$480000.0, which was down 13321.8% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Other Working Capital Changes peaked at $3.9 million during Q2 2024, and registered a low of -$1.5 million during Q3 2022.
  • Its 4-year average for Other Working Capital Changes is $658800.0, with a median of $606000.0 in 2025.
  • The largest annual percentage gain for Day One Biopharmaceuticals' Other Working Capital Changes in the last 5 years was 30705.47% (2023), contrasted with its biggest fall of 23080.57% (2023).
  • Over the past 4 years, Day One Biopharmaceuticals' Other Working Capital Changes (Quarter) stood at -$567000.0 in 2022, then soared by 307.05% to $1.2 million in 2023, then crashed by 77.51% to $264000.0 in 2024, then plummeted by 281.82% to -$480000.0 in 2025.
  • Its last three reported values are -$480000.0 in Q3 2025, $1.1 million for Q2 2025, and $606000.0 during Q1 2025.